Four patents currently held, every record listed here
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Feb 2041. from the record
Of the 2 now held by other companies, 2 name Gilgamesh Pharma Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2041
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2022 to 2043.
US 11,344,510
Arylcyclohexylamine Derivatives and Their Use in the Treatment of Psychiatric Disorders
Dec 28, 2040
US 12,157,722
Crystalline Hydrochloride Salts of N-ETHYL-2-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine
Sep 14, 2043
US 12,180,158
Crystalline Fumarate Salts of N-ETHYL-2-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine
Sep 14, 2043
US 12,129,234
Crystalline Salts of N-ETHYL-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine
Sep 14, 2043
202620302034203820422043
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
19 pending applications: term is not computable until grant.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends no later than Feb 2041 · Low confidence
Also notable
Ends Sep 2043 · High confidence
Methods of Treating Mood Disorders
US 11,440,879
The most cited patent in this portfolio, cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2041. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Crystalline Fumarate Salts of N-ETHYL-2-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine
US 12,180,158
Granted 2024. Too new for citation comparison; protection runs to 2043.
Formerly held, still cited
Notable
Ends Dec 2040 · High confidence
The earliest of the three still in force, granted 2022 and renewed since. Its term ends first, in 2040.
now held by Gilgamesh Pharma, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Crystalline Hydrochloride Salts of N-ETHYL-2-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine | 2 in force | to Sep 2043 |
| Crystalline Salts of N-ETHYL-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine | 1 in force | to Sep 2043 |
| Methods of Treating Mood Disorders | 1 in force | to Feb 2041 |
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,440,879 | Methods of Treating Mood Disorders In force · Low confidence | In force | Low confidence | |
| US 12,129,234 | Crystalline Salts of N-ETHYL-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine In force · High confidence | In force | High confidence | |
| US 12,157,722 | Crystalline Hydrochloride Salts of N-ETHYL-2-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine In force · High confidence | In force | High confidence | |
| US 12,180,158 | Crystalline Fumarate Salts of N-ETHYL-2-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 2 patents in force now held by others · 19 applications pending · 4 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.